Furthermore, various groups have combined ctDNA concentration with other biomarkers, such as AFP [78] and DCP [79], in order to increase its diagnostic accuracy (85% sensitivity and 93% specificity to distinguish patients with HCC from those without) [79]. The gene discussed is AFP; the disease is hepatocellular carcinoma.